![Gregory Brown](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Gregory Brown
Président chez
LISATA THERAPEUTICS, INC.
Fortune : 513 751 $ au 31/05/2026
Profil
Gregory B. Brown is the founder of Healthcare Royalty Management LLC, founded in 2007.
Current jobs include Chief Executive Officer & Director at Memgen, Inc. since 2018; Chairman at Aquestive Therapeutics, Inc. since 2024; Chairman at Lisata Therapeutics, Inc. since 2017; Director at Oscient Pharmaceuticals Corp.
since 2006; Director at Adimab LLC since 2023; and Advisory Board member at Femhealth Ventures LLC since 2022.
Former jobs include Chairman at Invuity, Inc. in 2015; Chairman at Nuron Biotech, Inc.; Director at Cambrex Corp.
from 2017 to 2019; Independent Non-Executive Director at Faron Pharmaceuticals Oy from 2017 to 2023; Director at Caladrius Biosciences, Inc. from 2016 to 2017; Director at PharmacoPhotonics, Inc.; Director at Vanderbilt Clinical SARL; Partner at Paul Capital Partners LP from 2003 to 2006; Head-Investment Banking & Healthcare at Adams Harkness & Hill Investment Banking from 1997 to 2002; Biotechnology Analyst at Vector Securities LLC from 1992 to 1997; Vice President-Finance at Vector Securities International, Inc.; and partner at Paul Capital Partners (United Kingdom) from 2003 to 2006.
Education includes a doctorate from SUNY Upstate Medical University in 1979, an undergraduate degree from Yale University in 1975, and an MBA from Harvard Business School in 1992.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 10/06/2026 | 75 085 ( 0,06% ) | 301 842 $ | 31/05/2026 | |
| 09/01/2026 | 65 203 ( 0,72% ) | 211 910 $ | 31/05/2026 |
Postes actifs de Gregory Brown
| Sociétés | Poste | Début |
|---|---|---|
| AQUESTIVE THERAPEUTICS, INC. | Président | 01/04/2024 |
| LISATA THERAPEUTICS, INC. | Président | 16/02/2017 |
Femhealth Ventures LLC
 Femhealth Ventures LLC Investment ManagersFinance Femhealth Ventures invests in companies located in the United States. The firm focuses on the health sector. It provides financing for early stage capital requirements. | Consultant / Advisor | 01/01/2022 |
Memgen, Inc.
 Memgen, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures immuno-oncology drugs | Directeur Général | 01/01/2018 |
Oscient Pharmaceuticals Corp.
 Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Markets and sells products to community-based primary care physicians | Directeur/Membre du Conseil | 01/08/2006 |
Healthcare Royalty Management LLC
 Healthcare Royalty Management LLC Investment ManagersFinance Healthcare Royalty invests in companies located in the United States. The firm targets companies operating in the field of biopharmaceutical, biotechnology and medical device sectors. It provides financing for buyout transactions in the form of royalty monetization, corporate financing and debt. | Fondateur | 01/01/2007 |
Adimab LLC
 Adimab LLC BiotechnologyHealth Technology Operates as a biologics discovery and engineering company that develops antibody drugs | Directeur/Membre du Conseil | 01/01/2023 |
Anciens postes connus de Gregory Brown
| Sociétés | Poste | Fin |
|---|---|---|
| FARON PHARMACEUTICALS OY | Directeur/Membre du Conseil | 24/03/2023 |
| CAMBREX CORPORATION | Directeur/Membre du Conseil | 04/12/2019 |
| ░░░░░░░ ░░░ | ░░░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░ ░░░░░░░░ ░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
| ░░░░ ░░░░░░░ ░░░░░░░░ ░░░░░░░ ░░░░░░░░ | ░░░░░░░ ░░░░░░ ░░░░░░░░ | ░░░░░░░░░░ |
Formation de Gregory Brown
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
96
Relations au 1er degré
22
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 22 |
|---|---|
Cambrex Corp.
 Cambrex Corp. Pharmaceuticals: GenericHealth Technology Develops and manufactures drug substances | Health Technology |
Oscient Pharmaceuticals Corp.
Oscient Pharmaceuticals Corp. Miscellaneous Commercial ServicesCommercial Services Markets and sells products to community-based primary care physicians | Commercial Services |
Invuity, Inc.
 Invuity, Inc. Medical SpecialtiesHealth Technology Develops medical devices surgical field applications | Health Technology |
Aquestive Therapeutics, Inc.
 Aquestive Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops & commercializes thin film pharmaceutical and over the counter drug products | Health Technology |
Adimab LLC
Adimab LLC BiotechnologyHealth Technology Operates as a biologics discovery and engineering company that develops antibody drugs | Health Technology |
PharmacoPhotonics, Inc.
 PharmacoPhotonics, Inc. Electronic Equipment/InstrumentsElectronic Technology Develops detection devices for measuring kidney injury functioning | Electronic Technology |
Paul Capital Partners LP
 Paul Capital Partners LP Investment ManagersFinance Paul Capital Partners' investment platforms include the Paul Capital Fund of Funds, secondary investments and commercial-stage healthcare investments. The Paul Capital Fund of Funds investment team focuses on investments in venture capital and small-cap buyouts. The firm invests in funds that support innovative products and business models. They take takes a lead investment role and actively seek advisory board seats. Their strategy is both growth and value oriented. The Paul Capital Fund of Funds venture capital investment strategy focuses on providing access to top-tier venture capital managers. The firm looks for emerging managers that have the potential to become industry leaders. They employ a multi-industry investment strategy that focuses on information technology, healthcare and clean technology. Most investments are made in early-stage companies, but some investments are made in late-stage and growth equity to provide reduced volatility and more rapid exits. The strategy is biased towards small funds and is balanced by a short list of larger funds or platforms. Paul Capital invests primarily in funds in the Silicon Valley and Boston, with growing exposure to select international investments. They make secondary investments in top tier managers obtained through the secondary market to mitigate the effect of the typical J-Curve associated with private equity fund investing. The Paul Capital Fund of Funds small-cap buyout investment strategy focuses on investments in a small-cap buyout funds in North America. They invest in small-cap buyout funds that are being raised by managers who are focused on buying companies with enterprise values of $300 million or less. To select the best performing managers, Paul Capital's process begins with a large universe of buyout relationships and ends with a focused and diversified small-cap buyout portfolio. The portfolio is complemented by co-investments and by investments in target funds obtained through the secondary market. The Paul Capital Fund of Funds co-investment strategy focuses on co-investments alongside general partners that are well-known to the firm and who require capital to close pending small-cap buyout and growth equity transactions. Investments are made directly in the securities of the portfolio company. The Fund of Funds team invests directly in portfolio companies across a full range of economic and credit cycles. For investors requiring exposure to both the firm's venture capital and small-cap buyout funds, Paul Capital provides customized solutions that allow participation in both activities over a multi-year period with a desired percentage allocation to each. Large investors seeking increased exposure to emerging managers, growth equity funds or buyout funds larger than their small-cap target (but generally less than $2 billion in size) can be accommodated through a separate account relationship. Paul Capital provides secondary transaction solutions for various sellers including pension plans, financial institutions, endowments, family offices, corporations and general partners. They help sellers reallocate their portfolio across asset types and classes, achieve early liquidity from private equity investments and obtain follow-on capital for existing portfolios and other objectives. Paul Capital Healthcare employs a variety of financing options ranging from non-dilutive financings that include royalty and revenue interest financings, to more traditional instruments such as equity and structured debt. Their clients include public and private companies, academic institutions and inventors. Paul Capital Healthcare helps companies monetize their royalty streams by selling all or a portion of these future royalties in exchange for an upfront payment and, depending on the structure, potential future payments. Paul Capital Healthcare invests in healthcare products that are approved and are generating revenue or are near commercialization. Healthcare companies should have an identifiable and established market, have patent and/or regulatory protection and be marketed by a strong organization. Paul Capital Healthcare employs the use of synthetic royalties or revenue interest financings. The firm provides a company with an upfront payment and future payments in exchange for a percentage of future product revenues. These deals are structured in a way that is similar to licensing agreements. They employ tiered revenues, reverse tiers, minimum payments, caps, step-downs and buy-out options. The deals are different from a standard licensing agreement in that Paul Capital Healthcare is not responsible for commercializing the product and is not involved in the company's daily operations. The firm makes an upfront payment to the company and, in some cases, additional payments based on certain milestones, such as regulatory approvals, patent extensions and sales targets. Paul Capital Healthcare then receives a portion of the future revenues generated by the product(s). Paul Capital Healthcare provides structured debt financing for small to mid-sized healthcare companies looking to expand operations. They can structure mezzanine-like debt in combination with revenue interests or royalty financings and the purchase of equities. Paul Capital Healthcare also structures traditional equity investments, usually in combination with revenue interest and royalty financings. The Fund participates in early-stage financing rounds in syndication with venture funds and in PIPE-style offerings. Paul Capital Healthcare focuses on near market or commercial-stage investments. | Finance |
Adams Harkness & Hill Investment Banking
 Adams Harkness & Hill Investment Banking Investment ManagersFinance Part of Canaccord Genuity Group, Inc., Adams Harkness & Hill Investment Banking is a company based in Boston, MA. | Finance |
Vector Securities LLC
 Vector Securities LLC Investment Banks/BrokersFinance Provides investment banking services | Finance |
SUNY Upstate Medical University
 SUNY Upstate Medical University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Yale University
 Yale University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Faron Pharmaceuticals Oy
 Faron Pharmaceuticals Oy Pharmaceuticals: MajorHealth Technology Operates as a clinical stage biopharmaceutical company | Health Technology |
Caladrius Biosciences, Inc.
 Caladrius Biosciences, Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops and commercializes cellular therapies products | Health Technology |
Vector Securities International, Inc.
 Vector Securities International, Inc. Investment Banks/BrokersFinance Security Brokers Dealers And Flotation Companies | Finance |
Healthcare Royalty Management LLC
Healthcare Royalty Management LLC Investment ManagersFinance Healthcare Royalty invests in companies located in the United States. The firm targets companies operating in the field of biopharmaceutical, biotechnology and medical device sectors. It provides financing for buyout transactions in the form of royalty monetization, corporate financing and debt. | Finance |
Memgen, Inc.
Memgen, Inc. Pharmaceuticals: MajorHealth Technology Develops and manufactures immuno-oncology drugs | Health Technology |
Nuron Biotech, Inc.
 Nuron Biotech, Inc. BiotechnologyHealth Technology Markets and develops vaccines for the prevention and treatment of infectious diseases | Health Technology |
Harvard Business School
 Harvard Business School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Vanderbilt Clinical SARL
 Vanderbilt Clinical SARL Financial ConglomeratesFinance Provides investment services | Finance |
Paul Capital Partners (United Kingdom)
 Paul Capital Partners (United Kingdom) Investment ManagersFinance Provides investment consulting services | Finance |
Femhealth Ventures LLC
Femhealth Ventures LLC Investment ManagersFinance Femhealth Ventures invests in companies located in the United States. The firm focuses on the health sector. It provides financing for early stage capital requirements. | Finance |
Lisata Therapeutics, Inc.
 Lisata Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops biopharmaceuticals | Health Technology |
